Biology Reference
In-Depth Information
Alving, A.S., et al., 1960. Mitigation of the haemolytic effect of primaquine and enhance-
ment of its action against exoerythrocytic forms of the Chesson strain of
Plasmodium
vivax
by intermittent regimens of drug administration. Bull. World Health Organ. 22,
621-631.
Anstey, N.M., et al., 2009. The pathophysiology of vivax malaria. Trends Parasitol. 25, 220-
227.
Anthony, M., et al., 2012. The global pipeline of new medicines for the control and elimina-
tion of malaria. Malar. J. 11 (1), 316.
Arevalo-Herrera, M., Chitnis, C., Herrera, S., 2010. Current status of
Plasmodium vivax
vac-
cine. Hum. Vaccin. 6 (1), 124-132.
Assefa, A., et al., 2010. Therapeutic efficacy of Artemether/Lumefantrine (Coartem(R))
against
Plasmodium falciparum
in Kersa, South West Ethiopia. Parasit. Vectors 3 (1), 1.
Austin, S.C., Stolley, P.D., Lasky, T., 1992. The history of malariotherapy for neurosyphilis.
Modern parallels. JAMA 268 (4), 516-519.
Awab, G.R., et al., 2010. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax
malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar. J. 9 (1), 105.
Baird, J.K., Hoffman, S.L., 2004. Primaquine therapy for malaria. Clin. Infect. Dis. 39, 1336-
1345.
Baird, J.K., Surjadjaja, C., 2010. Consideration of ethics in primaquine therapy against
malaria transmission. Trends Parasitol. 7 (1), 11-16.
Baird, J.K., Rieckmann, K.H., 2003. Can primaquine therapy for vivax malaria be improved?.
Trends Parasitol. 19, 115-120.
Baird, J.K., et al., 1995. Treatment of chloroquine-resistant
Plasmodium vivax
with chloro-
quine and primaquine or halofantrine. J. Infect. Dis. 171 (6), 1678-1682.
Baird, J.K., et al., 1997. In vivo resistance to chloroquine by
Plasmodium vivax
and
Plasmodium
falciparum
at Nabire, Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 56 (6), 627-631.
Baird, J.K., 2007. Neglect of
Plasmodium vivax
malaria. Trends Parasitol. 23 (11), 533-539.
Baird, J.K., 2009. Resistance to therapies for infection by
Plasmodium vivax
. Clin. Microbiol.
Rev. 22 (3), 508-534.
Baird, J.K., 2011. Radical cure: the case for anti-relapse therapy against all malarias. Clin.
Infect. Dis. 52 (5), 621-623.
Barcus, M.J., et al., 2007. Demographic risk factors for severe and fatal vivax and falciparum
malaria among hospital admissions in Northeastern Indonesian Papua. Am. J. Trop. Med.
Hyg. 77 (5), 984-991.
Bassat, Q., Alonso, P.L., 2011. Defying malaria: fathoming severe
Plasmodium vivax
disease.
Nat. Med. 17 (1), 48-49.
Beg, M.A., et al., 2008. Comparative features and outcomes of malaria at a tertiary care hos-
pital in Karachi, Pakistan. Int. J. Infect. Dis. 12 (1), 37-42.
Beier, J.C., 1998. Malaria parasite development in mosquitoes. Annu. Rev. Entomol. 43,
519-543.
Belkin, J.N., Knight, K.L., Rozeboom, L.E., 1945. Anopheline mosquitoes of The Solomon
Islands and New Hebrides. J. Parasitol. 31 (4), 241-265.
Beutler, E., Vulliamy, T.J., 2002. Hematologically important mutations: glucose-6-phosphate
dehydrogenase. Blood Cells Mol. Dis. 28 (2), 93-103.
Bharti, A.R., et al., 2006. Experimental infection of the neotropical malaria vector Anoph-
eles darlingi by human patient-derived
Plasmodium vivax
in the Peruvian Amazon. Am.
J. Trop. Med. Hyg. 75 (4), 610-616.
Bousema, T., Drakeley, C., 2011.
Plasmodium falciparum
and
Plasmodium vivax
gametocytes
- their epidemiology and infectivity in relation to malaria control and elimination. Clin.
Microbiol. Rev. 24 (2), 377-410.
Boyd, M.F., 1938. The threshold of parasite density in relation to clinical activity in primary
infections with
Plasmodium vivax
. Am. J. Trop. Med. s1-18 (5), 497-503.
